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Background: Candida spp. are a frequent cause of nosocomial bloodstream infections 
worldwide.
Objective: To evaluate the use patterns and outcomes associated with intravenous (IV) 
  fluconazole therapy in intensive care units in Spain and Germany.
Patients and methods: The research reported here was a prospective multicenter longitudinal 
observational study in adult intensive care unit patients receiving IV fluconazole. Demographic, 
microbiologic, therapy success, length of hospital stay, adverse event, and all-cause mortality data 
were collected at 14 sites in Spain and five in Germany, from February 2004 to November 2005.
Results: Patients (n = 303) received prophylaxis (n = 29), empiric therapy (n = 140), preemptive 
therapy (n = 85), or definitive therapy (n = 49). A total of 298 patients (98.4%) were treated 
with IV fluconazole as first-line therapy. The treating physicians judged therapy successful 
in 66% of prophylactic, 55% of empiric, 45% of preemptive, and 43% of definitive group 
patients. In the subgroup of 152 patients with proven and specified Candida infection only, 
32%   suffered from Candida specified as potentially resistant to IV fluconazole. The overall 
mortality rate was 42%.
Conclusion: Our study informs treatment decision makers that approximately 32% of the 
patients with microbiological results available suffered from Candida specified as potentially 
resistant to IV fluconazole, highlighting the importance of appropriate therapy.
Keywords: antifungal agents, Candida, fungal infection, therapy
Introduction
Candida spp. are a frequent cause of nosocomial bloodstream infections worldwide.1–7 
Candida albicans is the most prevalent species found in blood cultures, although an 
increasing proportion of Candida bloodstream isolates due to non-albicans   Candida 
have also been reported in many countries.8,9 The most frequent non-albicans   Candida 
spp. reported in Spain and Germany have been found to be C. parapsilosis and 
C. glabrata, respectively.6,10
Despite the frequency of occurrence of invasive candidiasis and the high associated 
mortality rates, this condition remains difficult to diagnose because of the prevalence 
of colonization without accompanying infection, nonspecific symptoms, and variable 
presentation. Diagnosis is therefore increasingly based on surrogate markers such 
as persistent pyrexia despite broad-spectrum antibiotic use, raised serum C-reactive 
protein, and the presence of other individual risk factors.1,4,11
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Once a diagnosis is made, azoles, polyenes, or echinocan-
dins are typically selected for treatment. Many agents have 
efficacy- or safety-related limitations. Drug resistance and 
lack of coverage of non-albicans Candida is an issue with 
fluconazole.8,12,13 Amphotericin B products are associated 
with renal and other toxicities,14,15 while drug interactions 
are common with itraconazole and voriconazole.3,16 Once 
an agent is selected, it is necessary to determine whether 
the patient requires antifungal prophylaxis, empiric therapy, 
preemptive therapy, or definitive (sometimes referred to as 
“targeted”) antifungal therapy.4
Definitive evidence supporting the use of these strate-
gies in the intensive care unit (ICU) is lacking. While a few 
  studies have shown that fluconazole therapy may be beneficial 
when used in certain critically ill surgical ICU patients,1,17–19 
treatment failure was observed more often in studies that also 
included C. krusei infections.20,21 Moreover, some studies 
indicate that prophylactic and empiric use of fluconazole 
may shift the flora towards non-C. albicans with decreased 
susceptibility to fluconazole.22 In a recently published French 
study, in vitro susceptibility to fluconazole was higher in 
patients naive to azole agents (84%) than in patients previ-
ously exposed to azole agents (70%).9
The morbidity, mortality, and health care costs associated 
with invasive fungal infections warrant further exploration 
in the ICU patient population to determine the effectiveness 
of prophylaxis as well as empiric, preemptive, and definitive 
therapies. To begin addressing these issues, we conducted 
a prospective study to evaluate the utilization patterns and 
outcomes associated with intravenous (IV) fluconazole 
therapy within hospital ICUs in Spain and Germany. The 
epidemiological results as well as clinical and therapeutic 
aspects of the study are presented in this paper.
Patients and methods
Study design and patient population
This prospective multicenter longitudinal real-world obser-
vational study was designed to collect demographic, all-
cause mortality, therapy response, and length of hospital 
stay data on adult ICU patients receiving IV azole therapy 
for the treatment of fungal infections. The study was con-
ducted at 19 sites, 14 in Spain and five in Germany, from 
  February 2004 to November 2005. Study patients were 
observed until discharge from the hospital or death, so that the 
data collection period was dependent on the length of hospital 
stay. The study was submitted to the responsible ethics com-
mittees in accordance with local regulations, and a positive 
decision (approval) was made: in Germany, by the Ethical 
Review Board of the Bavarian State Chamber of Physicians, 
Munich, Germany (Bayerische Landesärztekammer Ethik 
Kommission Nummer 03099) and, in Spain, by the Ethical 
Review Board of the of the Bellvitge Hospital, Barcelona, 
Spain (Comité Ético De Investigación Clínico ref 225/03). 
Data collection was conducted in accordance with the ethi-
cal standards outlined in the Declaration of Helsinki23 and 
Guideline for Good Clinical Practice.24
Eligible patients were those who were admitted to the 
ICU or surgical ICU during the study period, initiated an 
azole intravenously during ICU/surgical ICU admission, 
were between 18 and 100 years old, had signed informed 
consent, and were not on an investigational azole. Attending 
physicians were responsible for selecting the antifungal 
therapy.
Study procedures
Efficacy and safety assessments
Internet-based electronic case report forms were used to col-
lect patient data. Demographic characteristics included age, 
weight, sex, race, and medical history. Antifungal treatment 
characteristics (prophylaxis; empiric, preemptive, and/or 
definitive therapy),4 drugs received, and duration of therapy 
were recorded. Information on comorbidities and predispos-
ing risk factors was collected. Severity of illness measures, 
including Acute Physiology and Chronic Health Evaluation 
(APACHE) II scores, and Sequential Organ Failure Assess-
ment (SOFA) scores, were calculated for all patients at the 
start of IV fluconazole therapy. Microbiological information 
included dates, type, site of cultures (primarily sterile or pri-
marily non-sterile), and identification of isolates. Location 
and duration of hospital stay from initiation of IV fluconazole 
treatment to hospital discharge, hospital discharge diagnosis, 
and clinical outcomes and mortality were also recorded. 
Drug interactions and adverse events were recorded for all 
concomitant medications administered during the ICU stay 
while the patient was receiving IV fluconazole.
During a hospital stay, antifungal therapy may often 
change for a patient. Therefore, the number of treatment 
cycles within a hospital stay with fluconazole and non-
fluconazole was determined. A “treatment cycle” was defined 
as a period of consecutive use of a particular antifungal drug, 
with no further specification regarding duration or dose, since 
this was an observational study.
During the course of treatment, cultures from primar-
ily sterile and primarily non-sterile sites were collected for 
isolate identification from each patient at the time the treat-
ing physician decided to perform microbiological testing as 
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part of routine practice. Fungal cultures were incubated and 
isolates identified according to standardized procedures at 
the individual site.
Definitions of therapeutic response
All prophylaxis and therapy definitions were made prospec-
tively during the initial study design according to the Revised 
1994 British Society for Antimicrobial Chemotherapy 
Working Party definitions, as described by Flanagan and 
Barnes.4 The treating physician was responsible for assign-
ing individuals to one of these categories based on clinical 
and microbiological information. Predefined criteria for 
successful therapy according to treatment arm are depicted 
in Figure 1. Prophylaxis, preemptive, and empiric therapy 
were considered unsuccessful if one or more of the criteria 
of successful treatment were not met. Definitive therapy 
was considered unsuccessful if there was no improvement 
in attributable symptoms and signs, and no improvement 
in attributable abnormalities detected by radiography, 
bronchoscopy, endoscopy, or other procedures. Successful 
empiric therapy also required absence of breakthrough fungal 
infections during the observation period – that is, the time of 
hospitalization. “Breakthrough infection” was defined as any 
identification of an isolate at least 5 days after initialization 
of IV fluconazole treatment in the prophylaxis and empiric 
therapy groups.
Finally, an assessment was made for patients with 
  mycology results available. Based on recent literature,9,12,13 
“Successful” therapy was defined by type of therapy. 
Prophylaxis therapy was considered successful if: patients survived for 7 days after completion of 
IV azole therapy; there was an absence of breakthrough fungal infections during the administration of 
IV azole therapy or within 7 days after completion of treatment; there was an absence of premature 
discontinuation of the study drug because of drug-related toxicity or lack of efficacy; in case of 
subsequently confirmed baseline fungal infection (culture from sterile site pre-initiation of IV azole), 
there was resolution of all attributable symptoms and signs and in all attributable abnormalities 
detected by radiography, bronchoscopy, endoscopy, or other procedures; there was a negative 
culture for fungal pathogens that did not need to be repeated to confirm. 
Successful empiric therapy was defined as: survival for 7 days after completion of IV azole therapy, 
resolution of all symptoms and signs (such as fever); absence of breakthrough fungal infections 
during administration of IV azole therapy or within 7 days after completion of therapy; absence of 
premature discontinuation of the study drug because of drug-related toxicity or lack of efficacy or 
drug–drug interaction; in case of subsequently confirmed baseline fungal infection (culture from  
sterile site pre-initiation of IV azole), resolution in all attributable symptoms and signs and in all  
attributable abnormalities detected by radiography, bronchoscopy, endoscopy, or other procedures; 
negative culture for fungal pathogens that did not need to be repeated to confirm. 
Successful preemptive therapy (complete response) was defined as: survival for 7 days after 
completion of IV azole therapy; resolution of all symptoms and signs (such as fever) and resolution of 
radiographic, endoscopic abnormalities; microbiologic eradication of colonized sites during 
administration of IV azole therapy or within 7 days after completion of therapy; absence of  
premature discontinuation of the study drug because of drug-related toxicity or lack of efficacy or 
drug–drug interaction; in case of subsequently confirmed baseline fungal infection (culture from  
sterile site pre-initiation of IV azole), there was resolution in all attributable symptoms and signs and 
in all attributable abnormalities detected by radiography, bronchoscopy, endoscopy, or other 
procedures; negative cultures for fungal pathogens  which did not require repetition for confirmation. 
Definitive therapy  was considered successful (complete response) if: patients survived for 7 days 
after completion of IV azole therapy; resolution occurred in all attributable symptoms and signs and 
in all attributable abnormalities detected by radiography, bronchoscopy, endoscopy, or other 
procedures; there was absence of breakthrough fungal infections during administration of IV azole 
therapy or within 7 days after completion of therapy; there was absence of premature 
discontinuation of the study drug because of drug-related toxicity or lack of efficacy or drug–drug 
interaction; cultures were negative for fungal pathogens and did not need to be repeated to confirm. 
Figure 1 Predefined definitions of successful therapy according to individual treatment arm.
Abbreviation: IV, intravenous.
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patients with Candida infection only were classified as poten-
tially sensitive versus potentially resistant to IV fluconazole 
treatment by a panel of physicians and microbiologists in 
case mycology results had been obtained at the individual 
sites. Candida spp. were classified as potentially sensitive 
to fluconazole treatment (C. albicans, C. parapsilosis, and 
C. guillermondii) or potentially resistant to fluconazole 
treatment (C. glabrata, C. krusei, and C. tropicalis). Patients 
suffering from both species potentially sensitive and poten-
tially resistant to fluconazole treatment were counted in the 
latter group. Patients having only nonspecified Candida 
spp. or non-Candida coinfection were excluded from these 
analyses.
Statistical analysis
An exploratory data analysis was conducted to identify pre-
dictors of successful fluconazole therapy by using a signifi-
cance level of 5%. Odds ratios (ORs) with corresponding 95% 
confidence intervals (CIs) were calculated for the association 
of the individual factor with   successful therapy. The follow-
ing characteristics were assessed based on the judgment of 
the treating physician: patient age . 64 years, female sex, 
patient weight $ 70 kg, APACHE II score, neutropenic status 
on admission to ICU, mechanical ventilation at initiation of 
prophylaxis/therapy, reason for fluconazole therapy, number 
of IV fluconazole treatment cycles, number of non-  fluconazole 
treatment cycles, number of cultures from primarily sterile 
sites, number of cultures from primarily non-sterile sites, 
C. albicans isolate, non-albicans Candida isolate, medical 
conditions (congenital disease, diabetes mellitus, endocrine 
disorders, ear nose throat disease and dental disease, eye 
problems and cataracts, gastrointestinal tract disease, geni-
tourinary disease, heart disease, hematological disease, 
hypertension, liver disease, lung disease, neoplastic disease, 
neurologic and psychiatric disease,   rheumatologic/skeletal 
disease, skin disease, vascular   disease), length of hospital 
stay, drug–drug interactions and adverse events related to 
fluconazole therapy, risk factors (active malignancy, acute 
renal failure, human immunodeficiency virus, recent broad-
spectrum antibiotic use, recent use of central venous catheter, 
diabetes mellitus, (continuous) renal replacement therapy 
including hemodialysis, immunosuppressive medication, 
neutropenia (absolute neutrophil count , 500 cells/µL), 
recent parenteral nutrition (hyperalimentation), prior fungal 
colonization, major surgery (within 30 days), trauma, solid 
organ transplantation, and overall number of risk factors. 
Model predictors were   determined based on literature 
review and expert clinical opinion. A panel of physicians, 
pharmacists, and statisticians   prioritized possible predictors 
of successful therapy based on relevant literature.
Risk factors were preselected for the next analysis 
step. Variables included in the model were significant at 
P # 0.20 in univariate models. A backward variable selection 
method, with a selection level of 5%, was used to identify 
the list of predictors for successful therapy. ORs with 95% 
CIs were calculated.
Results
Patient accounting and demographics
Patients (n = 325) were enrolled in one of four treatment arms 
at the discretion of the individual treating physician: prophy-
laxis (n = 29; 10%), empiric therapy (n = 140; 46%), pre-
emptive therapy (n = 85; 28%), or definitive therapy (n = 49; 
16%). Three patients were excluded due to lack of treatment 
information. Subsequent analyses focused only on patients 
who received IV fluconazole during their hospitalization. 
This resulted in the elimination of 19 additional patients 
(seven from Germany and twelve from Spain) who received 
other azoles. Thus, data for 303 patients (112 from Germany 
and 191 from Spain) were analyzed.
The final cohort of 303 patients on IV fluconazole therapy 
had a mean age of 60 ± 16 years. The mean APACHE II 
score was 19 ± 10, with the widest range of scores observed 
in patients in the definitive therapy group (21 ± 15; Table 1). 
SOFA scores ranged from four to 14, with a mean of nine. 
Seven percent of patients had neutropenic status at ICU 
admission (,500 cells/μL) and 82% were on mechanical 
ventilation when they entered the study. Major risk factors 
for developing fungal infections included recent use of broad-
spectrum antibiotics (95%), recent use of a central venous 
catheter (97%), the status of the patient’s recent parenteral 
nutrition (67%), major surgery within 30 days (69%), and 
acute renal failure (47%).
Mycology
Pathogens at treatment initiation of IV fluconazole therapy 
or under treatment with IV fluconazole were available from 
251 patients. In 131 of these 251 patients, only one species 
could be identified. Colonization with two species was 
present in 90 patients, with three species in 24 patients, and 
with four species in six patients. The number of patients 
  suffering from C. albicans-only infection was 87 patients 
(35%), whereas 63 patients (25%) did not suffer from 
C. albicans at all. Thirteen patients (5%) were infected with 
a   combination of Candida with non-Candida spp., which 
were mainly Aspergillus (nine patients, 4%).
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Table 1 General patient characteristics
Parameter All Prophylaxis Empiric  
therapy
Preemptive  
therapy
Definitive   
therapy
Total number of patients 303 29 140 85 49
Characteristic n (%) n (%) n (%) n (%) n (%)
Age
  ,65 years 162 (54%) 21 (72%) 84 (60%) 34 (40%) 23 (47%)
  $65 years 303 (47%) 8 (28%) 56 (40%) 51 (60%) 26 (53%)
Gender
  Male 209 (69%) 22 (76%) 102 (73%) 52 (61%) 33 (67%)
  Female 94 (31%) 7 (24%) 38 (27%) 33 (39%) 16 (33%)
Weight
  ,70 kg 79 (26%) 11 (38%) 29 (21%) 20 (24%) 19 (39%)
  $70 kg 224 (74%) 18 (62%) 111 (79%) 65 (76%) 30 (61%)
APACHE II score at start of antifungal treatment (mean ± SD) 19 ± 10 16 ± 7 19 ± 7 19 ± 8 21 ± 15
SOFA score at start of antifungal treatment (mean ± SD) 9 ± 5a 10 ± 5 8 ± 5 9 ± 4 7 ± 3
Neutropenic status at IcU admission , 500 cells/µL 20 (7%) 3 (10%) 14 (10%) 2 (2%) 1 (2%)
Mechanical ventilation at study entry 248 (82%) 22 (76%) 109 (78%) 75 (88%) 42 (86%)
Medical conditions before start of fluconazole therapy
  ,3 94 (31%) 14 (48%) 50 (36%) 19 (22%) 11 (23%)
Risk factors for developing fungal infections
  ,5 98 (32%) 4 (14%) 49 (35%) 28 (33%) 17 (35%)
  Active malignancy 60 (20%) 11 (38%) 27 (19%) 10 (12%) 12 (25%)
  Acute renal failure 141 (47%) 11 (38%) 62 (44%) 45 (53%) 23 (47%)
  AIDS/HIV infection 9 (3%) 2 (7%) 5 (4%) 2 (2%) 0
    Broad-spectrum antibiotic use immediately  
prior to IV fluconazole
287 (95%) 29 (100%) 130 (93%) 81 (95%) 47 (96%)
  Recent use of central venous catheter 293 (97%) 29 (100%) 134 (96%) 81 (96%) 49 (100%)
  Diabetes mellitus 92 (31%) 8 (28%) 37 (27%) 27 (32%) 20 (41%)
  CRRT 96 (32%) 10 (35%) 42 (30%) 32 (38%) 12 (25%)
  Immunosuppressive medication 51 (17%) 13 (45%) 25 (18%) 11 (13%) 2 (4%)
  Neutropenia (ANc , 500 cells/µL) 20 (7%) 3 (10%) 14 (10%) 2 (2%) 1 (2%)
  Recent parenteral nutrition 204 (67%) 21 (72%) 88 (63%) 60 (71%) 35 (71%)
  Organ transplantation 26 (9%) 13 (45%) 10 (7%) 2 (2%) 1 (2%)
  Prior fungal colonization 34 (11%) 1 (3%) 15 (11%) 13 (15%) 5 (10%)
  Major surgery (within 30 days) 210 (69%) 25 (86%) 95 (68%) 54 (64%) 36 (74%)
  Trauma 42 (14%) 4 (14%) 21 (15%) 12 (14%) 5 (10%)
Notes: Data are % of patients, unless otherwise indicated; an = 148.
Abbreviations: AIDS/HIV, acquired immunodeficiency syndrome/human immunodeficiency virus; ANc, absolute neutrophil count; APAcHE II, Acute Physiology and 
Chronic Health Evaluation II; CRRT, (continuous) renal replacement therapy including hemodialysis; ICU, intensive care unit; IV, intravenous; SOFA, Sequential Organ Failure 
Assessment.
The microbiology results of the 407 isolates are shown 
in Table 2. To sum, Candida was the most common isolate 
(393/407 isolates, 96.5%), with C. albicans in 190 isolates 
(46.6%), non-albicans Candida in 92 isolates (22.6%), and 
nonspecified Candida in 111 isolates (27.3%).   Aspergillus was 
the most prominent non-Candida isolate (n = 10; 2.5%).
Fluconazole therapy
Patients started antifungal therapy within 20.1 ± 16.8 days of 
being admitted to hospital and had their initial fluconazole 
therapy in 15.3 ± 15.1 days of being admitted to the ICU for 
the first time (Table 3). For 263/303 patients with at least 
one documented treatment dose available, the overall mean 
(median; minimum [min]/maximum [max]) loading dose 
was 648 mg/day (400 mg; 100 mg/1200 mg), and the high-
est follow-up prophylaxis/treatment dose was 543 mg/day 
(400 mg; min 50 mg/max 1600 mg). The mean loading 
and follow-up dose were (n = 17/29) 600 mg (400 mg; min 
200 mg/max 1200 mg) and 438 mg (400 mg; 50 mg/800 mg) 
for prophylaxis; for empiric therapy (n = 113/140), 650 mg 
(400 mg; min 100 mg/max 1200 mg) and 565 mg (400 mg; min 
100 mg/max 1600 mg); for preemptive therapy (n = 84/85), 
661 mg (400 mg; min 200 mg/max 1200 mg) and 537 mg (min 
200 mg/max 1200 mg); and for definitive therapy (n = 49/49), 
637 mg (400 mg; min 200 mg/max 1200 mg) and 539 mg 
(400 mg; min 200 mg/max 800 mg). A total of 298 patients 
(98%) initiated IV fluconazole as first-line therapy; 111 (99%) 
were from Germany and 187 (98%) were from Spain. 
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45%–82%) and empiric therapy was successful in 77 of 140 
(55%, 95% CI 46%–63%) patients. In the preemptive therapy 
group, complete response was present in 38 of 85 patients 
(45%, 95% CI 33%–59%). Complete response to defini-
tive therapy was evident in 21 of 49 patients (43%, 95% CI 
42%–58%; Figure 2). Overall, the success rate was 51% 
(78/152, 95% CI 43%–60%; Table 4).
In the prophylaxis and empiric therapy groups, 14/29 and 
101/140 patients, respectively, had at least one mycology 
result available. Breakthrough infections, clinically 
and/or microbiologically identified after at least 5 days of IV 
fluconazole therapy were present in ten patients (71% of 
the 14 patients with mycology results available and 34% of 
all 29 patients) in the prophylaxis group and in 38 patients 
(60% of the 63 patients with mycology results available and 
27% of all 140 patients) in the empiric therapy group. In 
patients with proven Candida infection, the proportion of 
patients suffering from an infection of C. glabrata, C. krusei 
and/or C. tropicalis – species regarded as potentially resistant 
to IV fluconazole – was 32% (49/152). Overall, the success 
rate by sensitivity of Candida spp. to fluconazole was 
58/103 for potentially sensitive Candida spp. (C. albicans, 
C. tropicalis, and C. guillermondii; 56%) and 20/49 for 
potentially resistant Candida spp. (C. glabrata, C. krusei, 
and C. tropicalis; 41%; Table 4).
Univariate analysis of association  
of successful therapy
An explorative data analysis was conducted. Crude ORs with 
corresponding 95% CIs were calculated. Statistically sig-
nificant associations (ORs, with 95% CIs not including 1.0) 
for the entire cohort were found for 11/48 characteristics 
examined. Factors associated with no treatment response, or 
indicating that treatment response was less likely, were found 
for: patient age $ 65 years (OR 0.46), number of non-IV 
fluconazole treatment cycles (OR 0.42), colonization with 
Candida not specified as C. albicans (OR 0.40), CRRT (OR 
0.36), potential drug–drug interactions (OR 0.55), and heart 
Table  2  Pathogens  (n  =  407)  isolated  at  initiation  or  on 
intravenous fluconazole treatment in 251 patients with mycology 
results available
Pathogen Number  
of isolates
% % of all specified   
Candidaa
Candida 393 96.5
  C. albicans 190 46.6 67.4
  C. glabrata 38 9.3 13.5
  C. krusei 9 2.2 3.2
  C. tropicalis 25 6.1 8.9
  C. parapsilosis 19 4.7 6.7
  C. guillermondii 1 0.3 0.3
  C. not specified 111 27.3
Aspergillus 10 2.5
Other fungib 4 1.0
Total 407 100.0
Notes:  aIncludes  C.  albicans,  C.  glabrata,  C.  krusei,  C.  tropicalis,  C.  parapsilosis, 
C. guillermondii (n = 282); bincludes Mucor, Scedosporium, Trichosporon.
Table 3 Antifungal therapy characteristics by treatment group
Characteristic All Prophylaxis Empiric  
therapy
Preemptive  
therapy
Definitive   
therapy
Time from hospital admission to antifungal therapy (days) 20.1 ± 16.8 12.3 ± 13.2 22.4 ± 20.1 19.3 ± 13.1 19.2 ± 12.4
Time from first IcU admission to initial IV fluconazole  
therapy (days)
15.3 ± 15.1   7.9 ± 10.3 16.3 ± 17.4 16.2 ± 13.4 15.6 ± 11.8
Initiation of IV fluconazole therapy
  First-line 298 (100%) 29 (100%) 140 (100%) 84 (99%) 45 (92%)
  Number of IV fluconazole treatment cycles 1.1 ± 0.3 1.0 ± 0.2 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3
Abbreviations: ICU, intensive care unit; IV, intravenous.
The remaining five patients who received fluconazole as 
second-line therapy had received oral fluconazole (n = 2), 
amphotericin B (n = 1), liposomal amphotericin B (n = 1), and 
caspofungin (n = 1) as first-line therapy. All patients in the 
prophylaxis and empiric therapy groups had IV fluconazole 
as first-line therapy, while 99% of patients in the preemptive 
therapy group and 92% of patients in the definitive therapy 
group had IV fluconazole as first-line therapy.
The mean length of hospital stay for patients from initiation 
of IV fluconazole therapy to ICU and hospital discharge was 
12.7 ± SD 16.1 days and 37.9 ± SD 46.9 days, respectively.
There were 124 adverse events related to fluconazole 
therapy in 31 of 303 patients (10.2%; of these, 22 were clini-
cal [18%] and 102 were laboratory [82%]). In 17 patients, 
fluconazole interacted with concomitant medications.
The overall mortality rate for this study was 42% 
(n = 127).
Outcomes of fluconazole therapy  
by type of therapy
Based on the judgment of the individual physician, pro-
phylaxis was successful in 19 of 29 patients (66%, 95% CI 
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disease (OR 0.57). A high OR, indicating that treatment 
success is more likely, was found for recent use of central 
venous catheter (OR 8.60).
Multivariate analysis
Risk factors were preselected for the next analysis. Only 
the empiric therapy model is presented here because only 
this arm recruited a sufficient number of patients for mul-
tivariate analyses (Table 5). The other treatment strategies 
Table  4  Treatment  response  by  sensitivity  to  fluconazole 
treatment in 152 patients with proven Candida infection only
Treatment  
response to  
IV fluconazole
Potentially  
sensitive
Potentially  
resistant
Total P*
Prophylaxis
  Failure 3 1 4 0.32
  Success 6 2 8 0.16
  Total 9 3 12
Empiric therapy
  Failure 18 12 30 0.27
  Success 25 9 34 0.01
  Total 43 21 64
Preemptive therapy
  Failure 12 8 20 0.37
  Success 17 5 22 0.01
  Total 29 13 42
Definitive therapy
  Failure 12 8 20 0.37
  Success 10 4 14 0.11
  Total 22 12 34
Total
  Failure 45 29 74 0.06
  Success 58 20 78 ,0.01
  Total 103 49 152
Notes:  *H0:proportion  =  0.5.  Potentially  sensitive  to  fluconazole  treatment: 
C. albicans, C. parapsilosis, and C. guillermondii. Potentially resistant to fluconazole 
treatment: C. glabrata, C. krusei, and C. tropicalis. Patients suffering from both species 
potentially sensitive and potentially resistant to fluconazole treatment were counted 
in the latter group.
Abbreviation: IV, intravenous.
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Figure 2 Complete response rates by treatment arm.
  (prophylaxis, preemptive, and definitive therapies) had 
sample sizes that were too small to afford multivariate 
analyses. A multivariate logistic regression model was cre-
ated to test for the significant predictors of empiric therapy 
success. In the multivariate logistic model for successful 
treatment with empiric therapy, the significant predictors 
were colonization with Candida not specified as C. albicans 
(OR 0.21, 95% CI 0.08–0.54) and CRRT (OR 0.24, 95% CI 
0.08–0.70), which were inversely associated with success-
ful empiric therapy, and prior fungal colonization (OR 9.36, 
95% CI 1.50–58.19), which was positively associated with 
successful empiric therapy.
Discussion
This is the largest prospective study to evaluate the real-world 
treatment patterns related to invasive fungal infection in the 
ICU setting in Spain and Germany. Many previous studies 
identifying potential risk factors for developing candidemia 
have been limited by population, which frequently involved 
either patients with hematologic or solid organ malignancies, 
and by data obtained from a single institution or over a long 
period of time to ensure an adequate number of cases.25–27 
Moreover, few studies were prospective in design and few 
focused on ICU populations.9
Table 5 Multivariate logistic regression for predictors of successful 
empiric therapy
Predictor Point estimate  
(OR)
95% confidence   
limits
Female gender 1.54 0.55; 4.34
colonization with Candida  
not specified as C. albicans
0.21 0.08; 0.54
  Antibiotic use 3.93 0.43; 35.54
  Major surgery within 30 days 1.70 0.60; 4.80
  Immunosuppressive medication 0.37 0.10; 1.47
  Recent parenteral nutrition 0.87 0.33; 2.34
CRRT 0.24 0.08; 0.70
Prior fungal colonization 9.36 1.50; 58.19
    Recent use of central venous  
catheter
1.03 0.06; 16.59
  Age $ 65 years 0.59 0.23; 1.52
  APACHE II score 0.95 0.89; 1.01
  Organ transplantation 1.26 0.13; 12.40
  Diabetes mellitus 3.08 0.98; 9.70
  Mechanical ventilation 0.54 0.17; 1.70
    Number of fluconazole  
treatment cycles
5.60 0.77; 40.67
    Neutropenia  
ANc , 500 cells/mL
4.87 0.57; 41.73
Note: Model predictors were determined based on literature review and expert 
clinical opinion.
Abbreviations: ANc, absolute neutrophil count; APAcHE, Acute Physiology and 
Chronic Health Evaluation; CRRT, (continuous) renal replacement therapy including 
hemodialysis; OR, odds ratio.
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Fluconazole prophylaxis can reduce the incidence 
of Candida infection and colonization in selected criti-
cally ill patients, in both the medical and the surgical ICU 
settings.2,7,17,28,29 The present study observed a complete 
response to IV fluconazole prophylaxis in 66% of patients. 
Studies have reported that early treatment with fluconazole 
has a favorable effect on the clinical course of high-risk 
patients and late antifungal treatment is associated with a 
poor prognosis.11,27,30,31 Complete response rate for flucon-
azole in our study was comparable to studies that included 
all Candida spp.20 but lower compared with those in which, 
for example, C. krusei was excluded.21 However, we also 
observed that therapeutic success was strongly associated 
with type of fluconazole therapy, with empiric, preemptive, 
and definitive therapies being less successful and associated 
with higher mortality rates. It should be mentioned that 
the number of prophylaxis patients in our study was lower 
than in the treatment groups but patients were younger and 
differed with regard to the risk factors of acquired immu-
nodeficiency syndrome/human immunodeficiency virus, 
use of immunosuppressive medications, and major surgery, 
which were relatively higher in number in the prophylaxis 
group compared with in the treatment groups. In addition, as 
fluconazole prophylaxis does not resolve resistant and non-
albicans Candida infections, this may contribute to the low 
response rates in our cohort. At least one isolate potentially 
resistant to IV fluconazole was identified in 86/407 isolates 
(21%). In patients with at least one isolate identified, a break-
through infection was found in 34% of all patients receiving 
prophylaxis with IV fluconazole and in 27% of all patients 
receiving empiric therapy. Very recently, in a French group 
studied over similar period, non-albicans Candida spp. (ie, 
C. glabrata, C. parapsilosis, C. krusei, and C. tropicalis) 
comprised almost half of the Candida isolates and reduced 
susceptibility to fluconazole was observed in 17.1% of 
Candida isolates.9
Interestingly, in 13 of 251 patients (5%), non-Candida 
fungal infection was diagnosed at least once, mainly 
  Aspergillus. This is in accordance with recently published 
data reporting a rate of 6.7% for Aspergillus in the ICU.32 
This certainly warrants further investigation.
It has been suggested that early therapy be initiated in 
high-risk patients due to the high mortality, prevalence of 
invasive candidiasis, and poor reliability of available diag-
nostic methods.29,33–35 The present study shows that empiric 
antifungal treatment is common in the ICU setting in Spain 
and Germany. While an expert panel of the Infectious Disease 
Society of America no longer favors first-line fluconazole 
treatment in patients with moderately severe to severe 
illness or patients who have had recent azole exposure,34 
European recommendations, which were valid at study 
initiation, focused on the use of fluconazole.29 The British 
Society for Antimicrobial Chemotherapy Working Party has 
recommended empiric therapy for surgical and ICU patients 
thought to have deep candidiasis but for whom microbiologic, 
histological, or serologic confirmation cannot be obtained.35 
This is also addressed in the most recent guidelines of the 
European Society of Clinical Microbiology and Infectious 
Diseases, which in addition downgraded fluconazole recom-
mendation in non-neutropenic patients from AI to CIII.36 In 
our study, CRRT and colonization with Candida not specified 
as C. albicans were the only significant negative predictors 
of successful therapy in the multivariate empiric model, the 
only arm with sufficient sample size to conduct multivari-
ate analysis. The risk factor “prior fungal colonization” was 
associated with successful therapy. This might be regarded 
as a positive bias in our study, as the treating physician had 
been alerted that this was a possible reason for clinical signs 
of unknown origin. Finally, recent use of central venous 
catheter could not be confirmed as a positive predictor of 
successful therapy outcome by multivariate analysis.
Many studies have reported a steady increase in the 
number and prevalence of non-albicans Candida, which 
account for 40%–60% of the species reported as causes of 
invasive disease.6,10,37–39 Some of these species have reduced 
susceptibility or intrinsic resistance to fluconazole, and 
the increasing use of azoles is thought to account for these 
changes.1,31 A monocentric study from Spain in 226 candi-
demia episodes conducted from 2004 to 2009 found that 
previous use of fluconazole is an independent risk factor for 
fluconazole-resistant candidemia.40 In the Spanish study, 
predictive factors for isolation of C. glabrata or C. krusei 
were neutropenia, chronic renal disease, and solid organ 
transplantation.   Interestingly, the authors found a relationship 
between C. krusei and immunocompromised patients, as well 
as C. glabrata and elderly patients with underlying medical 
diseases.40 A study of the evolving trends of candidiasis in 
an Italian ICU from the 1980s to 2000 found that the rate 
of invasive Candida infections and colonization appeared 
stable, but there were an increased number of mixed colo-
nizations (39% versus 6%), a reduction of colonization by 
C. albicans (78% versus 93%), and increased C. glabrata 
involvement (35%).10 In the study reported here, we report 
mono-colonization with C. albicans in only 87/251 patients 
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(35%) with mycology results   available. Prophylactic use of 
fluconazole can shift the flora in the ICU away from C. albi-
cans toward   different fungal organisms.41 However, the use 
of early therapy may explain why overall candidal infection 
rates remained stable in both Spain and Germany.6,10 Our data 
confirm the emergence of non-albicans Candida and moulds, 
pathogens potentially resistant to fluconazole, in the ICU.
Treatment failure was high in both Candida spp. poten-
tially sensitive to fluconazole (44% of cases) and Candida 
spp. potentially resistant to fluconazole (59% of cases). These 
real-world outcomes in a heterogeneous population support 
findings from randomized clinical trials that also included 
C. krusei infections, reporting failure rates of 31%–64% in 
patients treated with fluconazole.20,21
Our study has several limitations, including the small 
sample size of most of the study arms. In addition,   causality 
cannot be demonstrated in an observational study and the 
assessments were based on evaluation by the treating physi-
cian and local diagnostic and treatment standards that were 
not reviewed by a panel. Information regarding the rationale 
for the use of fluconazole is limited and there are no data 
on detecting fluconazole-resistant yeast. Moreover, data on 
the base line of invasive fungal infection and colonization 
of each center were not collected and thus could not be 
considered as predictors of successful therapy. Based on 
current guidelines,34,36 some of the patients might not have 
been suitable for fluconazole treatment. Causes of the deaths 
were not recorded – although no death was considered related 
to fluconazole therapy – and the follow-up period after the 
end of fluconazole therapy was relatively short.
Conclusion
The prevalence of pathogens potentially resistant to flucon-
azole is evident in the intensive care setting in Germany 
and Spain. With empiric therapy being the most prevalent 
therapeutic strategy, more consideration needs to be given 
to selecting the appropriate agent for ICU patients. The 
importance of appropriate therapy is highlighted due to the 
fact that approximately 32% of the patients in our study with 
microbiological results available suffered from Candida 
specified as potentially resistant to fluconazole. Moreover, 
according to our data, fluconazole use for proven systemic 
albicans and non-albicans Candida infections was associated 
with treatment failure in about 50% of cases overall. Future 
studies may further help to elucidate whether early initiation 
of antifungal therapy with a broad-spectrum agent improves 
treatment outcomes in ICU populations.
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